SCHEMBL4808129

SCHEMBL4808129

CCOC(=O)c1ccc(OC[C@@H]2CCCN2OCC(=O)OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.57
CHRNA7 P36544 3/20 0.57
CHRNA4 P43681 3/20 0.57
CHRNA5 P30532 2/20 0.57
EGFR P00533 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 1/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
ADRB2 P07550 1/20 0.41
KCNH2 Q12809 2/20 0.41
MCHR1 Q99705 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433695 0.92 CHRNB2 (0.56) CHRNB2CHRNA7CHRNA4CHRNA5KDM4E
SCHEMBL5681974 0.89 CHRNB2 (0.52) CHRNB2CHRNA7CHRNA4CHRNA5EGFR
SCHEMBL4815476 0.86 CHRNB2 (0.58) CHRNB2CHRNA7CHRNA4CHRNA5EGFR
SCHEMBL3570241 0.84 GAA (0.45) CHRNB2CHRNA7CHRNA4CHRNA5L3MBTL1
SCHEMBL7370844 0.78 SMN1; SMN2 (0.55) L3MBTL1KDM4ELMNANPC1MAPK1
SCHEMBL2438025 0.76 CHRNB2 (0.57) CHRNB2CHRNA7CHRNA4CHRNA5KDM4E
SCHEMBL21522595 0.76 CHRNB2 (0.53) CHRNB2CHRNA7CHRNA4CHRNA5L3MBTL1
SCHEMBL2432680 0.74 KDM4E (0.43) CHRNB2CHRNA7CHRNA4CHRNA5L3MBTL1
SCHEMBL2434344 0.74 KDM4E (0.43) CHRNB2CHRNA7CHRNA4CHRNA5L3MBTL1
SCHEMBL7009532 0.74 KMT2A (0.58) L3MBTL1KDM4ELMNANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
EP-1623975-A1 PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105935-A1 Process for producing pyrrolidine derivative ACSL4, ALDH18A1, LTA CHRNB2 4677/4885CHRNA7 4295/4885CHRNA4 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.